Celleron Therapeutics enrols patients for clinical trial

20th August 2018

Celleron Therapeutics, spun out of the University in 2005, has commenced a Phase Ib/II clinical trial investigating drug combination therapy for colorectal cancer.

Following compelling pre-clinical results which demonstrate drugs working together to re-engage recognition of tumours by the immune system, this trial is investigating the clinical activity of CXD101 in combination with nivolumab.
The company is led by Professor Nick La Thangue, Founder and Chief Executive, and Professor of Cancer Biology in the Department of Oncology at Oxford University.

Further details are on the Celleron Therapeutics website.

Press release sign up

Ready to get in touch?

Contact Us
© Oxford University Innovation